Lithium increases platelet serine-9 phosphorylated GSK-3β levels in drug-free bipolar disorder during depressive episodes. (March 2015)

• Record Type: Journal Article
• Authors: de Sousa, Rafael T.; Zanetti, Marcus V.; Talib, Leda L.; Serpa, Mauricio H.; Chaim, Tiffany M.; Carvalho, Andre F.; Brunoni, Andre R.; Busatto, Geraldo F.; Gattaz, Wagner F.; Machado-Vieira, Rodrigo
• Is Part Of: Journal of psychiatric research. Volume 62(2015:Mar.)
• Page Start: 78
• Page End: 83
• Publication Date: 2015-03
• Subjects: Bipolar disorder -- GSK3 -- Lithium -- Treatment -- Depression -- Neurobiology; BD Bipolar Disorder -- GSK3β Glycogen synthase kinase-3β -- HAM-D 21-item Hamilton Depression Scale -- PBMC peripheral blood mononuclear cells -- phospho-GSK3β Serine-9 phosphorylated GSK3β -- SCID Structured Clinical Interview for Axis I DSM-IV-TR Disorders -- YMRS Young Mania Rating Scale; Psychiatry -- Periodicals; Mental Disorders -- Periodicals; Maladies mentales -- Périodiques; Psychiatry; Electronic journals; Periodicals; 616.89005
• DOI: 10.1016/j.jpsychires.2015.01.016
• Languages: English
• ISSNs: 0022-3956

Abstract

Abstract: Background: Glycogen synthase kinase-3 β (GSK3β) is an intracellular enzyme directly implicated in several neural processes relevant to bipolar disorder (BD) pathophysiology. GSK3β is also an important target for lithium and antidepressants. When phosphorylated at serine-9, GSK3β becomes inactive. Few studies evaluated serine-9 phosphorylated GSK3β (phospho-GSK3β) levels in BD subjects in vivo and no study has assessed it specifically in bipolar depression. Also, the effect of lithium monotherapy on GSK3β has never been studied in humans. Methods: In 27 patients with bipolar depression, total GSK3β and phospho-GSK3β were assessed in platelets by enzyme immunometric assay. Subjects were evaluated before and after 6 weeks of lithium treatment at therapeutic levels. Healthy subjects (n = 22) were used as a control group. Results: No differences in phospho-GSK3β or total GSK3β were observed when comparing drug-free BD subjects in depression and healthy controls. Baseline HAM-D scores were not correlated with phospho-GSK3β and total GSK3β levels. From baseline to endpoint, lithium treatment inactivated GSK3β by significantly increasing phospho-GSK3β levels (p = 0.010). Clinical improvement (baseline HAM-D — endpoint HAM-D) negatively correlated with the increase in phospho-GSK3β (p = 0.03). Conclusion: The present results show that lithium inactivates platelet GSK3β in BD during mood episodes. No direct association with pathophysiology of BD was observed. Further studies are needed to clarify the role of GSK3β as a key biomarker in BD and its association with treatment response as well as the relevance of GSK3β in other neuropsychiatric disorders and as a new therapeutic target per se . Highlights: Glycogen synthase kinase-3β (GSK3β) is inactive in phosphorylated form phospho-GSK3β. GSK3β was evaluated in drug-free bipolar disorder (BD) patients during depression. Phospho-GSK3β and total GSK3β were not different in BD subjects compared to controls. Depressive symptoms were not correlated with phospho-GSK3β and total GSK3β levels. From baseline to endpoint, lithium significantly increased phospho-GSK3β levels.